FP04.04 A Phase Ib/II Study of Imprime PGG and Pembrolizumab in Pretreated Patients With Advanced Stage Non-Small Cell Lung Cancer: BTCRC-LUN15-017

Abstract

Imprime PGG (imprime), a β-glucan, acts as a pathogen-associated molecular pattern and creates critical “non-self” signals recognized by the innate immune system. It enhances immune cell killing, activation of antigen-presenting cells, and T cell crosstalk, thereby may increase the anti-tumor efficacy of immune checkpoint inhibitors (ICI). Imprime is safe in combination with chemotherapy at 4 mg/kg on days 1, 8, and 15 of the 21-day cycle; however, not studied with ICI in non-small cell lung cancer (NSCLC).